Previously, many leukemia therapies were developed based on targeting leukemic cell-intrinsic attributes at the molecular level, such as cell cycle regulatory proteins, constitutively activated tyrosine kinase or cytokine receptor signaling, as well as genetic alterations that drive cell malignancy. Here, RCC1 is linked to leukemia.